Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512470-10-00

Acronym

CHD005-17

Enrollment

136

Registered

2024-04-09

Start date

2018-02-02

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA vasculitis, End-stage Renal disease

Brief summary

The primary end point will be the time between randomization and the first severe prejudicial event (severe infection, major AAV relapse, death) during 24 months of follow-up.

Interventions

DRUGRITUXIMAB

DRUGImurel 25 mg tabletter

DRUGAZATHIOPRINE

DRUGPREDNISONE

DRUGCORTANCYL 20 mg

DRUGcomprimé sécable

DRUGMycophenolate mofetil Tillomed 500 mg film-coated tablets

DRUGMYCOPHENOLIC ACID

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary end point will be the time between randomization and the first severe prejudicial event (severe infection, major AAV relapse, death) during 24 months of follow-up.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026